Literature DB >> 27231440

A SPECIAL MEETING REVIEW EDITION: CCFA/Advances in Inflammatory Bowel Diseases 2015: Highlights in Ulcerative Colitis and Crohn's Disease: A Review of Selected Presentations From the CCFA/Advances in Inflammatory Bowel Diseases 2015 Clinical and Research Conference • December 10-12, 2015 • Orlando, FloridaSpecial Reporting on:• New and Future Adhesion Molecule-Based Therapies in IBD• Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice• A Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-Severe Crohn's Disease Refractory to Anti-TNFα: UNITI-1• Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease• Does Vedolizumab Affect Postoperative Outcomes in Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease?PLUS Meeting Abstract Summaries With Expert Commentary by: Gary R. Lichtenstein, MDProfessor of MedicineDirector, Center for Inflammatory Bowel DiseaseUniversity of Pennsylvania Health SystemHospital of the University of PennsylvaniaPhiladelphia, Pennsylvania.

.   

Abstract

Entities:  

Year:  2016        PMID: 27231440      PMCID: PMC4875563     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  18 in total

1.  Five-Year Period Prevalence and Characteristics of Anemia in a Large US Inflammatory Bowel Disease Cohort.

Authors:  Ioannis E Koutroubakis; Claudia Ramos-Rivers; Miguel Regueiro; Efstratios Koutroumpakis; Benjamin Click; Marc Schwartz; Jason Swoger; Leonard Baidoo; Jana G Hashash; Arthur Barrie; Michael A Dunn; David G Binion
Journal:  J Clin Gastroenterol       Date:  2016-09       Impact factor: 3.062

Review 2.  Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

Authors:  Ivana Bravatà; Mariangela Allocca; Gionata Fiorino; Silvio Danese
Journal:  Curr Opin Pharmacol       Date:  2015-12       Impact factor: 5.547

3.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

4.  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

Authors:  Séverine Vermeire; Sharon O'Byrne; Mary Keir; Marna Williams; Timothy T Lu; John C Mansfield; Christopher A Lamb; Brian G Feagan; Julian Panes; Azucena Salas; Daniel C Baumgart; Stefan Schreiber; Iris Dotan; William J Sandborn; Gaik W Tew; Diana Luca; Meina T Tang; Lauri Diehl; Jeffrey Eastham-Anderson; Gert De Hertogh; Clementine Perrier; Jackson G Egen; John A Kirby; Gert van Assche; Paul Rutgeerts
Journal:  Lancet       Date:  2014-05-09       Impact factor: 79.321

5.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

6.  Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.

Authors:  Faten N Aberra; James D Lewis; David Hass; John L Rombeau; Benjamin Osborne; Gary R Lichtenstein
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

Review 7.  Biologics in inflammatory bowel disease: what are the data?

Authors:  Justin Côté-Daigneault; Mickael Bouin; Raymond Lahaie; Jean-Frédéric Colombel; Pierre Poitras
Journal:  United European Gastroenterol J       Date:  2015-10       Impact factor: 4.623

Review 8.  Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.

Authors:  Zain Kassam; Christine H Lee; Yuhong Yuan; Richard H Hunt
Journal:  Am J Gastroenterol       Date:  2013-03-19       Impact factor: 10.864

Review 9.  Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.

Authors:  Anne Tuskey; Brian W Behm
Journal:  Clin Exp Gastroenterol       Date:  2014-05-23

10.  A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

View more
  1 in total

1.  A New Model of Spontaneous Colitis in Mice Induced by Deletion of an RNA m6A Methyltransferase Component METTL14 in T Cells.

Authors:  Thomas X Lu; Zhong Zheng; Linda Zhang; Hui-Lung Sun; Marc Bissonnette; Haochu Huang; Chuan He
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.